Key TakeawaysAbbVie reduced its current quarter outlook related to costs from its acquisition of ImmunoGen.The drug maker announced the $10.1 billion purchase in November, giving it access to ImmunoGen's key ovarian cancer treatment.AbbVie reiterated its full-year outlook, taking into account effects of its purchase of Immunogen and pending acquisition of Cerevel Therapeutics.Drug maker AbbVie (ABBV) is lowering its current quarter guidance because of costs related to its acquisition of ImmunoGen.AbbVie red ...

AbbVie Inc.’s stock ABBV, -0.41% fell 0.5% early Monday, after the drug company lowered its first-quarter guidance to reflect the dilutive impact of its closure of the acquisition of ImmunoGen. The company said it now expects first-quarter per-share earnings to range from $2.26 to $2.30, down from prior guidance of $2.30 to $2.34, including a 4 cent per share dilutive impact from the Immunogen deal. AbbVie announced the $10.1 billion all-cash deal for Immunogen in November, that includes ImmunoGen’s antibo ...

Adds flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio ImmunoGen's pipeline complements AbbVie's existing oncology pipeline with potential to be transformative across multiple solid tumors and hematologic malignancies ImmunoGen's late-stage development programs for ELAHERE provide opportunity to expand into earlier lines of therapy and additional patient populations AbbVie ...

If you're looking to generate passive income in the new year, there are plenty of ways to do so that don't involve starting a second job or freelance gig. As you work toward your short-term and long-term financial goals, investing is one of many ways you can grow wealth with time.Dividend stocks can help you build your passive income streams, because you can benefit not just from the share price performance of the business, but from regular (usually quarterly) dividend distributions. There are dividend stoc ...

There are thousands of drugs on the market, and there are thousands more that are no longer in use. However, none has been more successful in terms of sales than AbbVie's (ABBV -0.41%) Humira. That's why investors were rightly concerned when the immunology medicine ran out of patent exclusivity in the U.S. last year. AbbVie's CEO, Rick Gonzalez, called it the "largest loss of exclusivity event" in the history of the industry.However, AbbVie saw this headwind coming from a mile away. Though its sales are dec ...

Core Insights - The article emphasizes the importance of strategic financial planning for retirement, focusing on capital allocation to businesses with strong financials and reliable earnings to ensure a comfortable retirement [7][8] - It highlights the need for a balanced approach that includes both stable income and moderate growth to combat inflation and maintain purchasing power over an extended retirement period [7][8] Retirement Planning - The average life expectancy in the country is 81.2 years, indicating that retirees may need to plan for potentially two decades of retirement [2] - A stable income from investments is essential, but there is also a need for growth in the portfolio to keep pace with inflation [2] Investment Characteristics - Key characteristics of a retirement portfolio should include durable businesses, strong balance sheets, high-quality non-cyclical earnings, and safe, growing dividends [2] - Retirees often make the mistake of chasing high dividend yields without considering the associated risks, as seen in companies like Altria and British American Tobacco [2][3] Portfolio Construction - A sample retirement portfolio is constructed with a projected yield of 5%, generating an annual income of $50,133 before taxes [6] - The portfolio includes a mix of individual stocks and one ETF for diversification, focusing on companies with strong dividend growth and capital appreciation potential [4][6] Individual Stock Analysis - Schwab US Dividend Equity ETF is highlighted for its sustainable and high-quality dividends, with a return on equity of 37.3% [6] - Enterprise Products Partners offers a stable business model with a distribution yield of 7.85% and expected EPS growth of 5% annually [6] - Realty Income is noted for its stable business model and diversified tenant base, providing a 5.8% dividend yield [6] - Allianz, the only European stock in the portfolio, has a solid dividend yield of 4.7% and is expected to grow its EPS by 6.3% over the next three years [6] - AbbVie, despite facing challenges, has a diversified portfolio and a 3.6% dividend yield with expected growth of 6.5% [6] - NextEra Energy is recognized for its commitment to clean energy and a well-covered dividend yield of 3.32% [6] - Ares Capital, as a Business Development Company, offers a high dividend yield of 9.6% but has seen a decrease in distribution [6] - Texas Instruments is noted for its strong dividend growth of 12.8% over the past five years [6] - PepsiCo and McDonald's are highlighted as defensive picks, with steady growth and reliable dividends [6] Conclusion - The article concludes that achieving financial freedom and a comfortable retirement is possible through careful planning and strategic investment in quality businesses [8]

Investors know the phrase “let your winners run,” but it’s easier said than done. The temptation to take profits off the table is often too great to ignore. By doing so, however, we run the risk of undercutting our portfolio returns. Having said that, you can’t go wrong with these stocks that just hit 52-week highs. There are quite a few winning stocks at 52-week highs that investors should continue to let run. The following three stocks may be at new peaks, but they have plenty of room to move higher still ...

Catherine Ledner/Stone via Getty Images Foreword As a supplement to this article, please note that Kiplinger has published an on-line slide-show detailing the latest 2024 S&P Dividend Aristocrats. The article, entitled The S&P 500 Dividend Aristocrats, is by Dan Burrows, a contributing editor. S&P Dow Jones Indices rebalances the S&P 500 Dividend Aristocrats every January; the Aristocratic population now stands at 67. There were two changes to the Dividend Aristocrats announced in January 2024. Walgreen ...

AbbVie to maintain exclusive access to Calibr-Skaggs' switchable CAR-T (sCAR-T) platform to develop novel cell therapy candidates against solid tumor targets identified by AbbVie AbbVie also has the option to explore the applicability of Calibr-Skaggs' sCAR-T platform in autoimmune diseases Calibr-Skaggs to partner with AbbVie to support discovery of next-generation sCAR-Ts using genetic medicine-based approaches LA JOLLA, Calif., Feb. 6, 2024 /PRNewswire/ -- The Calibr-Skaggs Institute for Innovative Med ...

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this drugmaker have returned +6.1%, compared to the Zacks S&P 500 composite's +5.3% change. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVie falls in, has gained 4.6%. The key question now is: What could be the stock's future direction?Although media reports ...